ARTICLE | Company News
Amarillo, Atrix interferon deal
October 2, 2001 7:00 AM UTC
AMAR granted ATRX rights to an oral low-dose interferon-alpha to treat Behcet's disease and oral papillomavirus warts in HIV-positive patients. AMAR will receive $485,000 and is eligible for milestone...